TRL HDL and CVD APK
最新バージョン
1.1.0 for Windows
更新しました
2017年January11日
情報
バージョン 1.1.0 (#3)
更新しました 2017年January11日
APKファイルサイズ 25.2 MB
Android 要件 Android 4.0+ (Ice Cream Sandwich)
開発元 Abannan Digital Solutions
カテゴリー 医療 (アプリケーション)
アプリケーションのID com.abannanuk.trlhdlandcvdhandheld
開発者ノート TRL HDL and CVD Handbook for Clinicians
スクリーンショット画像
画像をクリックするとフルサイズで表示されます
新機能
TRL HDL and CVD 1.1.0の新機能
Bug fixes and performance enhancements
説明
Triglyceride-rich lipoproteins and high-density lipoprotein in cardiometabolic disease: Therapeutics old and new - M. John Chapman and Henry N. Ginsberg on behalf of the EAS Consensus Panel.
Elevated triglyceride-rich lipoproteins (TRL), for which triglycerides are a marker, and low plasma concentrations of high-density lipoprotein cholesterol (HDL-C), often referred to as atherogenic dyslipidaemia, is a common risk factor for cardiometabolic disease, even among individuals who achieve target level of low-density lipoprotein cholesterol (LDL-C). Both are also key components of the metabolic syndrome, a pre-diabetic state. Atherogenic dyslipidaemia is also a key driver of cardiovascular risk in individuals with metabolic syndrome or diabetes.
The 2011 ESC/EAS Guidelines for Management of Dyslipidaemia include recommendations for the management of elevated triglycerides and/or low HDL-C after achievement of LDL-C goals. Despite this, management is still far from optimal.
This Handbook authored by Professors Chapman and Ginsberg on behalf of the European Atherosclerosis Society Consensus Panel, provides a unique accessible reference for clinicians. The Handbook provides a comprehensive background to HDL and TRL, and their relevance to cardiometabolic disease, and addresses the ongoing controversies surrounding HDL biology and its clinical relevance. Recommendations for clinical management of atherogenic dyslipidaemia are discussed in the context of the recent ESC/EAS Guidelines for Management of Dyslipidaemia.
The Handbook deals with practical issues in measurement, provides recommendations for treatment, and discusses emerging novel therapies. Case reports are a key feature to guide clinicians in their routine practice.
Website: http://www.eas-society.org
Elevated triglyceride-rich lipoproteins (TRL), for which triglycerides are a marker, and low plasma concentrations of high-density lipoprotein cholesterol (HDL-C), often referred to as atherogenic dyslipidaemia, is a common risk factor for cardiometabolic disease, even among individuals who achieve target level of low-density lipoprotein cholesterol (LDL-C). Both are also key components of the metabolic syndrome, a pre-diabetic state. Atherogenic dyslipidaemia is also a key driver of cardiovascular risk in individuals with metabolic syndrome or diabetes.
The 2011 ESC/EAS Guidelines for Management of Dyslipidaemia include recommendations for the management of elevated triglycerides and/or low HDL-C after achievement of LDL-C goals. Despite this, management is still far from optimal.
This Handbook authored by Professors Chapman and Ginsberg on behalf of the European Atherosclerosis Society Consensus Panel, provides a unique accessible reference for clinicians. The Handbook provides a comprehensive background to HDL and TRL, and their relevance to cardiometabolic disease, and addresses the ongoing controversies surrounding HDL biology and its clinical relevance. Recommendations for clinical management of atherogenic dyslipidaemia are discussed in the context of the recent ESC/EAS Guidelines for Management of Dyslipidaemia.
The Handbook deals with practical issues in measurement, provides recommendations for treatment, and discusses emerging novel therapies. Case reports are a key feature to guide clinicians in their routine practice.
Website: http://www.eas-society.org
評価とレビュー
評価: 4.0 / 5 · Less than 100 票
（*） 必要とされている
旧バージョン
類似のアイテム
「Abannan Digital Solutions」のその他のアイテム
最もダウンロードされたアプリとゲーム
